Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis

• Status: Completed
• Trial end date: 2016-12-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to establish if BMS-986202 is safe and effective at treating autoimmune diseases such as psoriasis. BMS-986202 which has shown some promise in preclinical studies for inhibiting autoimmune conditions such as psoriasis. This study will be the first time this drug is given to humans.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Famotidine; Interferon alpha-2; Interferon-alpha; Interferons; Ustekinumab

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Healthy Male and Female participants

• 18 to 50 years of age (Parts A-D)

• 18 to 70 years of age (Part E)

• Diagnosed with plaque psoriasis (Part E)

Exclusion Criteria:

• Participants that had recent infections

• Participants with Low Blood Pressure

• Participants with any heart related problems

• Participants with cancer

• Participants with any other major medical illness

Other protocol defined inclusion/exclusion criteria could apply